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Abstract
Objectives: Orofacial clefts are major human birth defects with complex etiology. Previous studies have proposed 
Transforming growth factor - beta 3 (TGF-β3) gene as a key player in contributing to non-syndromic cleft lip and 
palate, however none of the studies have yet included Indian population. Hence this study was designed to detect 
TGF-β3 gene polymorphism in nonsyndromic cleft lip and palate patients from Indian population which is geneti-
cally distinct from previously studied populations.
Study Design: Peripheral blood samples of forty non-syndromic cleft lip and palate patients and forty unaffected 
individuals were collected for a case – control study design. Ethical clearance from the institutional review board 
and informed consent from all subjects was obtained. DNA extracted from the cases and controls was amplified 
using polymerase chain reaction (PCR) with TGF-β3 specific primers. The obtained fragments were sequenced 
and TGF-β3 gene polymorphisms were assessed based on the number of CA repeats.  
Results: Chi –square test was used to compare the case and control groups. Results showed a significant difference 
in the number of CA repeats between the case and the control groups (p=0.01).  
Conclusion: This study confirms the crucial role of TGF-β3 in the fusion of palatal shelves during development 
and further, provides novel evidence of TGF-β3 gene polymorphism in the etiology of nonsyndromic cleft lip and 
palate in Indian subpopulation.
Key words: Orofacial clefts, nonsyndromic cleft lip with/without cleft palate, TGF-β3, Polymerase chain reaction, 
gene polymorphism.
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Introduction
Orofacial clefts, and in particular cleft lip and palate, 
are major human birth defects with complex etiology. 
Although specific genetic causes for some common-
forms of syndromic cleft lip and palate such as Van der 
Woude syndrome have been identified, the genes for 
non-syndromic clefting have been more elusive targets 
(1-3). Many genes have been proposed to play an impor-
tant role in the causation of cleft lip with/without cleft 
palate. Transforming Growth Factor-Beta 3 (TGF-β3) 
is one of the strongest candidate gene for cleft lip and 
palate in humans (4,5). TGF-β3 (located on 14q24) has 
a broad spectrum of biological activities and is known 
to induce palatal fusion (6) and in recent years a large 
number of studies have been conducted to elucidate the 
relationship of TGF-β3 and cleft lip and palate (7-9). 
As none of the studies included patients of the Indian 
subcontinent who are genetically distinct from the other 
study populations, this study was done to detect the 
presence of TGF-β3 gene polymorphisms in non syn-
dromic cleft lip and palate in Indian patients.
Materials and Methods   
-Patient samples: The study was approved by the Ethics 
Committee of Medical College Hospital. Forty patients 
with non-syndromic cleft lip with cleft palate were selected 
and informed consent was obtained. Subjects with known 
teratogenic exposure and other recognized syndromes as 
well as children with other major or multiple minor defects 
and/or developmental delay as determined from the demo-
graphic details, perinatal history, teratogenic exposure and 
family history were excluded. Forty unaffected individuals 
from the same geographic area who had no craniofacial 
anomaly or other congenital disease and no family history 
of craniofacial malformation were included in the study as 
controls. Peripheral blood sample (10 ml) was collected by 
venipuncture from all cases.  
-DNA extraction and amplification: A modified proto-
col for standard organic extraction method was used for 
DNA extraction from lymphocytes. Polymerase chain 
reactions were performed to amplify the extracted DNA 
samples and assessed for the allelic variants using spe-
cific primers for TGF-β3 gene. 
TGF-β3 primers:
Sense (Forward) primer: AGATTCTGGCTTCCACGAAA 
Antisense (reverse) primer: GCAAGCAGGGATAATA-
ACAGCA.
After completion of the PCR reaction, an agarose gel 
was run to identify amplified PCR products. These 
fragments were then cut out and subjected to to sequen-
cing PCR using the ABI prism Big. Dye Terminator 
Cycle sequencing ready reaction kit version 3.1. The 
product obtained from sequencing PCR was subjected 
to isopropanol precipitation to remove protein and other 
contaminants and then sent for sequencing. 
Analysis of Sequencing Results: The TGF-β3 gene has 
a CA repeat sequence, and the polymorphism is depen-
dent on the frequency of CA repeats. The sequences of 
the amplified DNA fragments of TGF-β3 gene were 
analyzed using Bioedit sequence analyzer software. 
-Statistical procedure used: Chi –square test was 
used to compare the case and control groups.
Results
The number of CA repeats in the DNA sequence of the 
cases was compared with the number of CA repeats in 
controls; 23 out of a total of 40 samples from the case 
group showed 10 CA repeats, whereas 14 of them had 9 
CA repeats and 3 samples had 6 CA repeats. In the control 
group 29 out of 40 samples had 9 CA repeats and only 11 
had 10 CA repeats (Table 1). The significance of the re-
sults obtained was statistically analyzed using chi-square 
test. A chi-square value of  > 5.99 and a ‘p’ value of <0.05 
is considered statistically significant. The chi-square cal-
culated with our data was 12.446 with a corresponding 
p value of 0.01. Thus, we observed that the difference 
between the Non-syndromic CLCP cases and the control 
group in terms of number of CA repeats representing the 
TGF-β3 polymorphisms is highly significant.
Table 1. Results of TGF-β3 Polymorphisms as determined by CA 
repeats in samples.

TGF beta 3 
Polymorphisms Controls
Subjects  
(Non-syndromic CLCP) 
9 CA repeats 29 14 
10 CA Repeats 11 23 
Others 0 3 
Total Cases 40 40 
Discussion 
The development of orofacial region relies on the in-
terplay of a vast range of genetic and epigenetic fac-
tors (10). When these factors are disrupted either at the 
gene level, due to mutations or by disruption of epi-
genetic regulation by environmental teratogens could 
lead to orofacial clefting. Patients with orofacial clefts 
require surgical, nutritional, dental, speech, medical 
and behavioral interventions and impose a substantial 
emotional and economic burden on the society. The-
se issues, along with the relatively high prevalence of 
orofacial clefts, emphasize the importance of unders-
tanding the underlying causes of these defects. Most 
orofacial clefts are caused by the interaction between 
genetic and environmental factors (11). Genetic fac-
tors create susceptibility for clefts, and when environ-
mental factors (ie, triggers) interact with a genetically 
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susceptible genotype, a cleft develops during an early 
stage of development (12). The organisation of the fa-
cial structures requires tissues to proliferate, fuse and 
differentiate. Palatogenesis involves fusion of the me-
dial edge epithelium (MEE) of the approximating pa-
latal shelves with each other via numerous desmosome 
contacts to form a midline palatal seam (13,14). This 
seam rapidly degenerates allowing mesenchymal cells 
to flow across the now intact horizontal palate. TGF-β3 
is found in the epithelial component of the shelves and 
in the medial edge epithelium (MEE). TGF-β3 plays a 
crucial role in these initial adhesive interactions (15). 
TGF-β3 knock out mouse exhibits cleft palate through 
failure of palatal shelf fusion (16). Although the pa-
latal shelves otherwise develop normally, they show 
a marked reduction in the filopodia and show down-
regulation of condroitin sulphate proteoglycan on the 
apical surface of the MEE (17,18), both of which  are 
required for efficient MEE adhesion (19,20). 
A large number of studies (21-24) have been carried 
out to elucidate the role of TGF-β3 gene polymor-
phisms in the etiopathogenesis of cleft lip and palate 
of which some studies, such as that of Vieira AR et 
al (5) on south American population and Lidral AC et 
al (22) on Philippine population, have yielded positi-
ve associations, while a few studies did not show any 
significant association, such as those of Tanabe A et al 
(23) and Jugessur A et al (24) conducted on Japanese 
and Norwegian population respectively. The prevalen-
ce of orofacial clefts is more common among Indians 
and oriental populations, where it occurs in 1 every 
500 births or higher (25). Inspite of this, there has 
been no major study thus far on Indian patients with 
non-syndromic CLCP. Our study was, hence, the first 
report on polymorphism in TGF-β3 gene in patients 
with non-syndromic cleft lip and palate of Indian ori-
gin. This study could provide a basis for more elabora-
te studies involving larger number of samples that can 
explore the specific role of TGF-β3gene in more detail 
in this population. 
The general failure to pinpoint the precise molecular 
events that lead to human cleft lip and palate most 
likely stems from our lack of knowledge about the 
gene networks and regulation of gene expression du-
ring palatal development. While studies such as ours 
are related to individual gene events, they could help 
by contributing to the existing scientific knowledge 
of inter-related gene networks, ultimately leading to 
a better understanding of the pathogenesis of cleft lip 
and palate. In addition to playing an important role in 
the development of palate, TGF-β3 also has some the-
rapeutic possibilities: exogenous TGF3 can correct the 
palatal fusion defect in TGF-β3-null embryos, raising 
the possibility of exogenous supplementation of TGF-
β3 as fetal therapy. Rather than a surgical approach, 
it is known that maternally-administered recombinant 
TGF-β3 can cross the mouse placental barrier. Exo-
genous TGF-β3 is also known to reduce the severity 
of scarring following wound healing in rats (26), rai-
sing the possibility that some individuals with cleft 
palate caused by genetic abnormalities in the TGF-β3 
pathway might be more prone to excessive scarring 
following surgical correction, thereby compounding 
an otherwise distressing abnormality. Exogenous 
application of TGF-β3 as an anti-scarring therapy at 
the time of surgical correction of the cleft may also be 
particularly beneficial to such individuals. 
In summary, our study highlights the role for TGF-β3 
in non-syndromic cleft lip and palate patients from the 
Indian sub-continent and points out a potential thera-
peutic intervention to correct the malady. 
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